Rafael Hartmann

Mr. Rafael Hartmann

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2018 in The Analyst
Verified
Journal Article
Open access
PDF file
MKMalin Källsten
Malin Källsten
RHRafael Hartmann
Rafael Hartmann
KAKonstantin Artemenko
Konstantin Artemenko
SLSara Bergström Lind
Sara Bergström Lind
FLFredrik Lehmann
Fredrik Lehmann
JBJonas Bergquist
Jonas Bergquist
Four different cysteine linked antibody-drug conjugates (ADCs) consisting of Trastuzumab-vc-MMAE were analysed with four common analytical techniques with respect to drug-to-antibody ratio (DAR) and molecular weight.

8 September 2020 in Antibodies
Verified
Journal Article
Open access
PDF file
MKMalin Källsten
Malin Källsten
RHRafael Hartmann
Rafael Hartmann
LKLucia Kovac
Lucia Kovac
FLFredrik Lehmann
Fredrik Lehmann
SLSara Bergström Lind
Sara Bergström Lind
JBJonas Bergquist
Jonas Bergquist
Antibody–drug conjugates (ADCs) are heterogeneous biotherapeutics and differ vastly in their physicochemical properties depending on their design. The number of small drug molecules covalently attached to each antibody molecule is commonly referred to as the drug-to-antibody ratio (DAR). Established analytical protocols for mass spectrometry (MS)-investigation of antibodies and ADCs often require sample treatment such as desalting or interchain disulfide bond reduction prior to analysis. Herein, the impact of the desalting and reduction steps—as well as the sample concentration and elapsed time between synthesis and analysis of DAR-values (as acquired by reversed phase liquid chromatography MS (RPLC–MS))—was investigated. It was found that the apparent DAR-values could fluctuate by up to 0.6 DAR units due to changes in the sample preparation workflow. For methods involving disulfide reduction by means of dithiothreitol (DTT), an acidic quench is recommended in order to increase DAR reliability. Furthermore, the addition of a desalting step was shown to benefit the ionization efficiencies in RPLC–MS. Finally, in the case of delayed analyses, samples can be stored at four degrees Celsius for up to one week but are better stored at −20 °C for longer periods of time. In conclusion, the results demonstrate that commonly used sample preparation procedures and storage conditions themselves may impact MS-derived DAR-values, which should be taken into account when evaluating analytical procedures.

16 October 2020 in ChemMedChem
Verified
Journal Article
Open access
PDF file
RHRafael Hartmann
Rafael Hartmann
RFRaphael Fahrner
Raphael Fahrner
DSDenys Shevshenko
Denys Shevshenko
MFMårten Fyrknäs
Mårten Fyrknäs
RLRolf Larsson
Rolf Larsson
LOLuke Odell
Luke Odell
Auristatins are a class of ultrapotent microtubule inhibitors, whose growing clinical popularity in oncology is based upon their use as payloads in antibody‐drug conjugates (ADCs). The most widely utilized auristatin, MMAE, has however been shown to cause apoptosis in non‐pathological cells proximal to the tumour (“bystander killing”). Herein, we introduce azastatins, a new class of auristatin derivatives encompassing a side chain amine for antibody conjugation. The synthesis of Cbz‐azastatin methyl ester, which included the C2‐elongation and diastereoselective reduction of two proteinogenic amino acids as key transformations, was accomplished in 22 steps and 0.76 % overall yield. While Cbz‐protected azastatin methyl ester (0.13–3.0 nM) inhibited proliferation more potently than MMAE (0.47–6.5 nM), removal of the Cbz‐group yielded dramatically increased IC50‐values (9.8–170 nM). We attribute the reduced apparent cytotoxicity of the deprotected azastatin methyl esters to a lack of membrane permeability. These results clearly establish the azastatins as a novel class of cytotoxic payloads ideally suited for use in next‐generation ADC development.

17 November 2021 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
RHRafael Hartmann
Rafael Hartmann
MPMatthijs Pijnappel
Matthijs Pijnappel
Johan NilvebrantJohan Nilvebrant
Johan Nilvebrant
HHHildur Run Helgudottir
Hildur Run Helgudottir
AAArni Asbjarnarson
Arni Asbjarnarson
LOLuke Odell
Luke Odell
The novel bioconjugation method makes use of maleimides and tris(2-carboxyethyl)phosphine (TCEP) to conjugate small molecules to proteins via alkenes.